Thomas A. Fitzgerald

RNAZ

CHIEF FINANCIAL OFFICER · TRANSCODE THERAPEUTICS, INC. · CIK 0001854168

FILING MIX · LIFETIME100%/0%

BUYS

SELLS

TOTAL VALUE

$40.4K

COMPANIES

ACTIVE SINCE

Feb 2022

HOLDINGS NOW

650,000

AVG SELL PX

—

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

2 backtested trades · 8 horizonsHow are these numbers computed? →

Forward-return performance of every backtestable P/S trade by Thomas A. Fitzgerald, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	2	+50.00%	-8.45%	+1.31%	-9.76%	-9.76%	—
14d	2	+0.00%	-11.30%	+2.27%	-13.57%	-13.57%	—
30d	2	+50.00%	-19.27%	+0.67%	-19.94%	-19.94%	—
60d	2	+50.00%	-28.55%	+11.77%	-40.31%	-40.31%	—
90d	2	+0.00%	-38.54%	+9.87%	-48.41%	-48.41%	—
180d	2	+0.00%	-79.00%	+16.25%	-95.25%	-95.25%	—
1y	2	+0.00%	-93.54%	+28.75%	-122.29%	-122.29%	—
2y	2	+0.00%	-99.92%	+55.13%	-155.05%	-155.05%	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

RNAZ · 650,000 shares · as of Jun 14, 2024

Trading cadence · quarterly flow

BUY ● SELL ●

2022

2023

2024

FLOW · 7 buys / 0 sellsCOVERAGE · 10 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
RNAZ TRANSCODE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	650,000	—	—	650,000	Jun 14, 2024	Jun 18, 2024 ↗	View →
RNAZ TRANSCODE THERAPEUTICS, INC.	PURCHASE Chief Financial Officer	49,350	$0.51	$25.2K	56,318	Sep 28, 2023	Oct 2, 2023 ↗	View →
RNAZ TRANSCODE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	300,000	—	—	300,000	May 19, 2023	May 19, 2023 ↗	View →
RNAZ TRANSCODE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	100,000	—	—	100,000	Dec 12, 2022	Dec 14, 2022 ↗	View →
RNAZ TRANSCODE THERAPEUTICS, INC.	PURCHASE Chief Financial Officer	12,000	$1.27	$15.2K	139,377	Jun 16, 2022	Jun 17, 2022 ↗	View →
RNAZ TRANSCODE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	52,000	—	—	52,000	Mar 1, 2022	Mar 2, 2022 ↗	View →
RNAZ TRANSCODE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	33,000	—	—	33,000	Feb 1, 2022	Feb 3, 2022 ↗	View →

Other insiders · RNAZ

Loading peer insiders…

About this filer

CIK 0001854168

ROLE

Chief Financial Officer

PRIMARY

RNAZ

COMPANIES

ACTIVE SINCE

Feb 2022

MARKETPEEL · /INSIDER/0001854168DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

Thomas A. Fitzgerald

The morning brief, before the bell.